Gelder Mark S. MD 4
4 · Onconova Therapeutics, Inc. · Filed Feb 9, 2022
Insider Transaction Report
Form 4
Gelder Mark S. MD
Chief Medical Officer
Transactions
- Award
Stock Option (right to purchase)
2022-02-07+51,750→ 51,750 totalExercise: $1.82Exp: 2032-02-07→ Common stock (51,750 underlying) - Award
Restricted Stock Units
2022-02-07+17,500→ 17,500 total→ Common stock (17,500 underlying)
Footnotes (3)
- [F1]These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
- [F2]These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.
- [F3]Each restricted stock unit is convertible into one share of common stock.